These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 32368173)

  • 21. Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment.
    Psimaras D; Velasco R; Birzu C; Tamburin S; Lustberg M; Bruna J; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S74-S85. PubMed ID: 31393660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor Therapy.
    Murakata Y; Tajiri K
    Intern Med; 2022 Jul; 61(14):2099-2100. PubMed ID: 35283387
    [No Abstract]   [Full Text] [Related]  

  • 23. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis.
    von Itzstein MS; Khan S; Gerber DE
    Clin Chem; 2020 Jun; 66(6):779-793. PubMed ID: 32363387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
    Nigro O; Pinotti G; De Galitiis F; Di Pietro FR; Giusti R; Filetti M; Bersanelli M; Lazzarin A; Bordi P; Catino A; Pizzutilo P; Galetta D; Marchetti P; Botticelli A; Scagnoli S; Russano M; Santini D; Torniai M; Berardi R; Ricciuti B; De Giglio A; Chiari R; Russo A; Adamo V; Tudini M; Silva RR; Bolzacchini E; Giordano M; Di Marino P; De Tursi M; Rijavec E; Ghidini M; Vallini I; Stucci LS; Tucci M; Pala L; Conforti F; Queirolo P; Tanda E; Spagnolo F; Cecchi F; Bracarda S; Macrini S; Santoni M; Battelli N; Fargnoli MC; Porzio G; Tuzi A; Suter MB; Ficorella C; Cortellini A
    Eur J Cancer; 2020 Jul; 134():19-28. PubMed ID: 32454395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
    Hall KH; Liu Y; Jiang C; Harvey RD
    Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
    Zhao JJ; Wen XZ; Ding Y; Li DD; Zhu BY; Li JJ; Weng DS; Zhang X; Zhang XS
    Aging (Albany NY); 2020 Jun; 12(11):10663-10675. PubMed ID: 32516130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
    Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
    Yao S; Li X; Nong J; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infectious complications in patients treated with immune checkpoint inhibitors.
    Karam JD; Noel N; Voisin AL; Lanoy E; Michot JM; Lambotte O
    Eur J Cancer; 2020 Dec; 141():137-142. PubMed ID: 33137589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer.
    Sebastiani GD; Scirocco C; Galeazzi M
    Autoimmun Rev; 2019 Aug; 18(8):805-813. PubMed ID: 31176871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocrine adverse effects of immune checkpoint inhibitors.
    Walters AGB; Braatvedt G
    Intern Med J; 2021 Jul; 51(7):1016-1020. PubMed ID: 34278695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Management of toxicities from immunotherapy].
    Heinrich K; von Bergwelt-Baildon M; Theurich S
    Dtsch Med Wochenschr; 2021 Sep; 146(17):1119-1128. PubMed ID: 34448188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients.
    Wood LS; Moldawer NP; Lewis C
    Clin J Oncol Nurs; 2019 Jun; 23(3):271-280. PubMed ID: 31099804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
    Fernandes S; Varlamov EV; McCartney S; Fleseriu M
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
    Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
    Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroid-related adverse events induced by immune checkpoint inhibitors.
    Chera A; Stancu AL; Bucur O
    Front Endocrinol (Lausanne); 2022; 13():1010279. PubMed ID: 36204105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune-related adverse events of immune checkpoint inhibitors: a brief review.
    Myers G
    Curr Oncol; 2018 Oct; 25(5):342-347. PubMed ID: 30464684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing Care for Patients With Adverse Events From Immunotherapeutics.
    Sheehan K; Price C; Hafez N
    Cancer J; 2020; 26(6):537-542. PubMed ID: 33298725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.